Category: Abiomed Inc.
The Medical Technology Veterans Program expands to include life sciences, adds BioCollaborative and names Mike Grice its new president.
The Medical Technology Veterans Program is broadening its scope, adding biotechnology, life sciences and diagnostic industries. The expansion comes with a new name for the group, now called the MedTech & BioTech Veterans Program.
Massachusetts-based Abiomed reports record Impella heart pump revenues during its 3rd quarter, with sales up 20% year-over-year.
Bay state medical device maker Abiomed (NSDQ:ABMD) reported another strong quarter, with revenues up 20% on record sales of its flagship Impella cardiac pump.
MassDevice.com looks into the tea leaves to peek at medtech's near future with our 3 predictions for the new year.
As we put a ribbon on 2013, another tumultuous year for the medical device industry, it's time to check the tea leaves for what medtech might expect in 2014.
These predictions are based on the 2,500 or so stories we've written this year about the medical device space, as well as conversations we've had with hundreds of industry leaders about their thoughts, concerns, annoyances and triumphs.
Prediction #1: The medical device tax will not survive 2014
Abiomed's former director of investor relations, Susan Vissers Lisa, jumps ship for Boston Scientific's IR vice president role.
Susan Vissers Lisa, the former director of investor relations at Abiomed (NSDQ:ABMD), was named vice president of IR at Boston Scientific (NYSE:BSX).
Company officials at Abiomed discuss the company's Q2 2014 earnings results. Abiomed logged profits of $1.1 million, or 3¢ per share, on sales of $44.3 million for the 3 months ended Sept. 30.
Abiomed shares flirt with a 52-week high after the medical device company reports strong fiscal 2nd-quarter sales growth and beats Wall Street's earnings expectations.
Abiomed (NSDQ:ABMD) shares approached a 52-week high this morning after the medical device company reported fiscal 2nd-quarter sales growth of nearly 19% and beat Wall Street's earnings forecast.
Abiomed shares surge on Medicare move to maintain reimbursement rates for the Impella heart pump.
Shares of Abiomed (NSDQ:ABMD) surged nearly 10% today after news broke that Medicare will maintain the reimbursement rate for its flagship Impella heart pump.